Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 7 (2010), Issue 1 (January)

1. Radical prostatectomy for high-risk prostate cancer.
   Jpn J Clin Oncol, 40(1): 3-9. [Abstract] [Full-text]
2. Docetaxel in combination with prednisolone for hormone refractory prostate cancer.
   Jpn J Clin Oncol, 40(1): 79-84. [Abstract] [Full-text]
3. Ceramide plays a prominent role in MDA-7/IL-24-induced cancer-specific apoptosis.
   J Cell Physiol, 222(3): 546-55. [Abstract] [Full-text]
4. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma.
   Int J Cancer, 126(5): 1166-76. [Abstract] [Full-text]
5. Altered expression of neurotensin receptors is associated with the differentiation state of prostate cancer.
   Cancer Res, 70(1): 347-56. [Abstract] [Full-text]
6. ErbB3 binding protein 1 represses metastasis-promoting gene anterior gradient protein 2 in prostate cancer.
   Cancer Res, 70(1): 240-8. [Abstract] [Full-text]
7. Alternative splicing of the cyclin D1 proto-oncogene is regulated by the RNA-binding protein Sam68.
   Cancer Res, 70(1): 229-39. [Abstract] [Full-text]
8. In vivo tumor grading of prostate cancer using quantitative 111In-capromab pendetide SPECT/CT.
   J Nucl Med, 51(1): 31-6. [Abstract] [Full-text]
9. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.
   J Natl Cancer Inst, 102(1): 39-46. [Abstract] [Full-text]
10. Predominant expression of CCL2 at the tumor site of prostate cancer patients directs a selective loss of immunological tolerance to CCL2 that could be amplified in a beneficial manner.
    J Immunol, 184(2): 1092-101. [Abstract] [Full-text]
11. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial.
    J Clin Oncol, 28(2): 340-7. [Abstract] [Full-text]
12. Androgen regulation of the prostatic tumour suppressor NKX3.1 is mediated by its 3' untranslated region.
    Biochem J, 425(3): 575-83. [Abstract] [Full-text]
13. The Ron receptor tyrosine kinase positively regulates angiogenic chemokine production in prostate cancer cells.
    Oncogene, 29(2): 214-26. [Abstract] [Full-text]
14. Longitudinal analysis of quality of life in patients receiving conformal radiation therapy for prostate cancer.
    Strahlenther Onkol, 186(1): 46-52. [Abstract] [Full-text]
15. ERK regulates calpain 2-induced androgen receptor proteolysis in CWR22 relapsed prostate tumor cell lines.
    J Biol Chem, 285(4): 2368-74. [Abstract] [Full-text]
16. A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy.
    Cancer Chemother Pharmacol, 65(4): 811-5. [Abstract] [Full-text]
17. Influence of omega-6 PUFA arachidonic acid and bone marrow adipocytes on metastatic spread from prostate cancer.
    Br J Cancer, 102(2): 403-13. [Abstract] [Full-text]
18. Mutation analysis of the MSMB gene in familial prostate cancer.
    Br J Cancer, 102(2): 414-8. [Abstract] [Full-text]
19. Clinical presentation and initial management of black men and white men with prostate cancer in the United Kingdom: the PROCESS cohort study.
    Br J Cancer, 102(2): 249-54. [Abstract] [Full-text]
20. Hedgehog signaling regulates proliferation of prostate cancer cells via stathmin1.
    Clin Exp Med, 10(1): 51-7. [Abstract] [Full-text]
21. Leptomeningeal metastases from prostate cancer: an emerging clinical conundrum.
    Clin Exp Metastasis, 27(1): 19-23. [Abstract] [Full-text]
22. Breast, colorectal, and prostate cancer risk in the European Prospective Investigation into Cancer and Nutrition-Norfolk in relation to phytoestrogen intake derived from an improved database.
    Am J Clin Nutr, 91(2): 440-8. [Abstract] [Full-text]
23. Prostate cancer: Comparison of 3D T2-weighted with conventional 2D T2-weighted imaging for image quality and tumor detection.
    AJR Am J Roentgenol, 194(2): 446-52. [Abstract] [Full-text]
24. Repeat prostate biopsy accuracy: simulator-based comparison of two- and three-dimensional transrectal US modalities.
    Radiology, 254(2): 587-94. [Abstract] [Full-text]
25. Dissecting the dynamics of serum prostate-specific antigen.
    Am J Clin Pathol, 133(2): 187-93. [Abstract] [Full-text]
26. Quality of life among elderly men treated for prostate cancer with either radical prostatectomy or external beam radiation therapy.
    J Cancer Res Clin Oncol, 136(3): 379-86. [Abstract] [Full-text]
27. Resonant Mie scattering (RMieS) correction of infrared spectra from highly scattering biological samples.
    Analyst, 135(2): 268-77. [Abstract] [Full-text]
28. The prostate cancer-associated human retrovirus XMRV lacks direct transforming activity but can induce low rates of transformation in cultured cells.
    J Virol, 84(4): 1874-80. [Abstract] [Full-text]
29. Variability in diagnostic opinion among pathologists for single small atypical foci in prostate biopsies.
    Am J Surg Pathol, 34(2): 169-77. [Abstract] [Full-text]
30. Does neoadjuvant hormonal therapy improve urinary function when given to men with large prostates undergoing prostate brachytherapy?
    J Urol, 183(2): 634-9. [Abstract] [Full-text]
31. Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance--does the risk of misclassification vary according to biopsy criteria?
    J Urol, 183(2): 539-44. [Abstract] [Full-text]
32. Performance of prostate cancer prevention trial risk calculator in a contemporary cohort screened for prostate cancer and diagnosed by extended prostate biopsy.
    J Urol, 183(2): 529-33. [Abstract] [Full-text]
33. Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program.
    J Urol, 183(2): 534-8. [Abstract] [Full-text]
34. An update of the Gleason grading system.
    J Urol, 183(2): 433-40. [Abstract] [Full-text]
35. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen.
    J Urol, 183(2): 520-7. [Abstract] [Full-text]
36. Impact of hormonal therapy on intermediate risk prostate cancer treated with combination brachytherapy and external beam irradiation.
    J Urol, 183(2): 546-50. [Abstract] [Full-text]
37. Any proportion of ductal adenocarcinoma in radical prostatectomy specimens predicts extraprostatic extension.
    Hum Pathol, 41(2): 281-5. [Abstract] [Full-text]
38. N-myc downstream regulated gene-1/Cap43 may play an important role in malignant progression of prostate cancer, in its close association with E-cadherin.
    Hum Pathol, 41(2): 214-22. [Abstract] [Full-text]
39. Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer.
    Cancer Immunol Immunother, 59(4): 529-40. [Abstract] [Full-text]

© 2004-2012 Prostate Cancer Research Today. All Rights Reserved.